Ongoing Projects
AROMICS has a clear international vision. From its inception, the company has participated in the establishment of a biotechnology strategy in Europe to improve commercial and production activities of small and medium size companies.
AROMICS has proven experience in R&D Projects under various funding programs: European (Horizon 2020), national (CDTI) and local (ACC1Ó-FEDER). The active participation of the company in European funded R&D projects as well as membership in different European platforms enables the company to:
- Be at the forefront of European research.
- Identify, improve and implant new technologies with potential applications in the health sector(industry and clinical practice).
- Favor technology transfer.
- Share the costs of innovation through partnerships with other biotechnology and pharmaceutical companies.
CLINBERMES
The aim of the project is to develop a novel treatment for Malignant Mesothelioma, a rare, aggresive and poorly responsive cancer directly related to asbestos exposure. General objective pursued by the project include to complete non-regulatory preclinical studies and conduct a clinical trial in patients.
(Co-financed by the Horizon 2020 Programme of the European Union)
(Co-financed by CDTI through the Horizon Europe EIC Accelerator Seal of Excellence SME Programme)
G4-CANCER
The aim of the project is to develop an innovative platform for screening anti-tumour drugs, based on the identification and characterisation of G-quadruplex (G4) structures in oncogenes. These structures, which are complex and highly regulatory in nature, play a key role in both tumour progression and mechanisms of resistance to conventional therapies, and are therefore therapeutic targets of great interest.
(Cofinanced by the program NUCLIS D’INNOVACIÓ TECNOLÒGICA - Projectes de Recerca Industrial i Desenvolupament Experimental - ACCIO 2022)
RNA targeting
Technical assessment and strategic definition of a family of RNA‑targeting molecules.
Support from ACCIÓ – Generalitat de Catalunya under the Cupons Propietat Industrial i Intel·lectual programme)